Highlights GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Real-time Estimate Cboe BZX Other stock markets 12:50:10 11/05/2024 am IST			5-day change	1st Jan Change
0.265 ^USD	-11.07%		-85.57%	-88.81%

07/05	Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50	MT
06/05	Sector Update: Health Care Stocks Higher in Late Afternoon Trading	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Higher in Late Afternoon Trading	07/05	MT
Sector Update: Health Care	07/05	MT
GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint	06/05	MT
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia	06/05	CI
GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
GlycoMimetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03	CI
GlycoMimetics, Inc. Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1A Healthy Volunteer Study of GMI-1687	04/01	CI
GlycoMimetics, Thermo Fisher Unit Set Accord for Manufacturing Uproleselan for Acute Myeloid Leukemia	03/01	MT
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687	06/23/06	CI
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/23/02	CI
GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia	15/23/15	CI
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	03/23/03	CI
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee	15/23/15	CI
GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting	12/22/12	CI
GlycoMimetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09	CI
Earnings Flash (GLYC) GLYCOMIMETICS Posts Q2 Loss $-0.25	03/22/03	MT
GlycoMimetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	03/22/03	CI
Earnings Flash (GLYC) GLYCOMIMETICS Posts Q1 Loss $-0.28, vs. Street Est of $-0.32	28/22/28	MT
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Highlights

Filters